Published in Curr Alzheimer Res on July 01, 2005
Motor control and aging: links to age-related brain structural, functional, and biochemical effects. Neurosci Biobehav Rev (2009) 3.50
Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci U S A (2005) 1.61
The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm (Vienna) (2006) 1.50
Muscarinic receptors and ligands in cancer. Am J Physiol Cell Physiol (2008) 1.42
Targeting of acetylcholinesterase in neurons in vivo: a dual processing function for the proline-rich membrane anchor subunit and the attachment domain on the catalytic subunit. J Neurosci (2009) 1.04
Impaired spatial working memory and altered choline acetyltransferase (CHAT) immunoreactivity and nicotinic receptor binding in rats exposed to intermittent hypoxia during sleep. Behav Brain Res (2007) 1.01
Revisiting the Role of Acetylcholinesterase in Alzheimer's Disease: Cross-Talk with P-tau and β-Amyloid. Front Mol Neurosci (2011) 0.97
Serum cholinesterases are differentially regulated in normal and dystrophin-deficient mutant mice. Front Mol Neurosci (2012) 0.83
Comparative study of korean white, red, and black ginseng extract on cholinesterase inhibitory activity and cholinergic function. J Ginseng Res (2011) 0.83
Intranasal administration of acetylcholinesterase inhibitors. BMC Neurosci (2008) 0.83
Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis. J Neural Transm (Vienna) (2008) 0.83
Anti-amnesic activity of Citrus aurantium flowers extract against scopolamine-induced memory impairments in rats. Neurol Sci (2014) 0.82
Prevention approaches in a preclinical canine model of Alzheimer's disease: benefits and challenges. Front Pharmacol (2014) 0.82
Assessment of acetylcholinesterase activity using indoxylacetate and comparison with the standard Ellman's method. Int J Mol Sci (2011) 0.82
Neuronal AChE splice variants and their non-hydrolytic functions: redefining a target of AChE inhibitors? Br J Pharmacol (2013) 0.82
Design, synthesis and biological activity of multifunctional α,β-unsaturated carbonyl scaffolds for Alzheimer's disease. Bioorg Med Chem Lett (2013) 0.82
Occupational and other risk factors for hand-grip strength: the Honolulu-Asia Aging Study. Occup Environ Med (2006) 0.79
Correlations between cholinesterase activity and cognitive scores in post-ischemic rats and patients with vascular dementia. Cell Mol Neurobiol (2011) 0.79
The effects of sesquiterpenes-rich extract of Alpinia oxyphylla Miq. on amyloid-β-induced cognitive impairment and neuronal abnormalities in the cortex and hippocampus of mice. Oxid Med Cell Longev (2014) 0.78
Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α-Synuclein synthesis, interleukin-1β release, and cholinergic action. Antiinflamm Antiallergy Agents Med Chem (2013) 0.78
Catalpol Induces Neuroprotection and Prevents Memory Dysfunction through the Cholinergic System and BDNF. Evid Based Complement Alternat Med (2013) 0.77
Compound danshen tablet ameliorated aβ25-35-induced spatial memory impairment in mice via rescuing imbalance between cytokines and neurotrophins. BMC Complement Altern Med (2014) 0.77
Neurobiology of the aging dog. Age (Dordr) (2010) 0.76
Development of an in-vivo active reversible butyrylcholinesterase inhibitor. Sci Rep (2016) 0.75
Cholinesterase inhibitors, donepezil and rivastigmine, attenuate spatial memory and cognitive flexibility impairment induced by acute ethanol in the Barnes maze task in rats. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.75
Synthesis and application of β-carbolines as novel multi-functional anti-Alzheimer's disease agents. Bioorg Med Chem Lett (2016) 0.75
Diagnosis of Intoxication by the Organophosphate VX: Comparison Between an Electrochemical Sensor and Ellman´s Photometric Method. Sensors (Basel) (2008) 0.75
Identification of potential herbal inhibitor of acetylcholinesterase associated Alzheimer's disorders using molecular docking and molecular dynamics simulation. Biochem Res Int (2014) 0.75
Expression of acetylcholinesterase 1 is associated with brood rearing status in the honey bee, Apis mellifera. Sci Rep (2017) 0.75
Deer bone extract prevents against scopolamine-induced memory impairment in mice. J Med Food (2014) 0.75
Cocaine cardiovascular effects and pharmacokinetics after treatment with the acetylcholinesterase inhibitor donepezil. Am J Addict (2016) 0.75
In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe. Nat Biotechnol (2005) 2.81
Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study. Report of three cases. J Neurosurg (2002) 2.45
Large-scale cellular-resolution gene profiling in human neocortex reveals species-specific molecular signatures. Cell (2012) 2.29
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci U S A (2009) 2.15
An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem (2002) 2.00
Tau, tangles, and Alzheimer's disease. Biochim Biophys Acta (2005) 1.82
Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro. Proc Natl Acad Sci U S A (2013) 1.55
Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther (2002) 1.51
Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer's disease. J Neurosci (2004) 1.48
Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromolecular Med (2002) 1.46
Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res (2003) 1.45
A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther (2002) 1.43
Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes (2008) 1.42
Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol (2006) 1.40
Plumbagin, a novel Nrf2/ARE activator, protects against cerebral ischemia. J Neurochem (2009) 1.39
TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr Alzheimer Res (2007) 1.38
GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis (2010) 1.36
Alzheimer's disease drug development in 2008 and beyond: problems and opportunities. Curr Alzheimer Res (2008) 1.33
Delayed treatment with a p53 inhibitor enhances recovery in stroke brain. Ann Neurol (2009) 1.31
TNF-α protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation. J Neuroinflammation (2012) 1.29
The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. J Pharmacol Exp Ther (2006) 1.29
A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr Drug Targets (2003) 1.28
The glucagon-like peptides: a double-edged therapeutic sword? Trends Pharmacol Sci (2003) 1.28
The role of p53-induced apoptosis in cerebral ischemia: effects of the p53 inhibitor pifithrin alpha. Exp Neurol (2004) 1.26
Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol (2005) 1.25
Hippocampal volume is associated with memory but not monmemory cognitive performance in patients with mild cognitive impairment. J Mol Neurosci (2003) 1.22
N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease. Curr Alzheimer Res (2012) 1.20
Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices? J Alzheimers Dis (2008) 1.20
p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann Neurol (2002) 1.19
A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis. Curr Alzheimer Res (2006) 1.18
Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases. CNS Neurol Disord Drug Targets (2011) 1.16
Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. J Alzheimers Dis (2006) 1.16
Critical role of TNF-α in cerebral aneurysm formation and progression to rupture. J Neuroinflammation (2014) 1.15
Tumor necrosis factor-α synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. J Neuroinflammation (2012) 1.13
Accumulation of aspartic acid421- and glutamic acid391-cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer disease. J Neuropathol Exp Neurol (2008) 1.11
Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr Alzheimer Res (2005) 1.11
Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol (2012) 1.10
Cholinergic changes in the APP23 transgenic mouse model of cerebral amyloidosis. J Neurosci (2002) 1.10
Lost in translation: neuropsychiatric drug development. Sci Transl Med (2010) 1.09
Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies. J Neurosci (2006) 1.09
Exendin-4 decreases amphetamine-induced locomotor activity. Physiol Behav (2012) 1.09
Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine. Proc Natl Acad Sci U S A (2007) 1.08
Presenilin-1 mutation impairs cholinergic modulation of synaptic plasticity and suppresses NMDA currents in hippocampus slices. Neurobiol Aging (2008) 1.07
Apoptotic and behavioral sequelae of mild brain trauma in mice. J Neurosci Res (2007) 1.07
Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity. J Neurochem (2006) 1.06
Rivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS One (2011) 1.06
TNF-α induces phenotypic modulation in cerebral vascular smooth muscle cells: implications for cerebral aneurysm pathology. J Cereb Blood Flow Metab (2013) 1.05
Targets for AD treatment: conflicting messages from γ-secretase inhibitors. J Neurochem (2011) 1.05
Tumor necrosis factor-α synthesis inhibitor, 3,6'-dithiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in mice. J Neurochem (2011) 1.04
The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain. Neuropharmacology (2008) 1.04
Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine. Neurochem Res (2007) 1.04
A possible link between astrocyte activation and tau nitration in Alzheimer's disease. Neurobiol Dis (2008) 1.01
The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity. Regul Pept (2003) 1.01
The KATP channel activator diazoxide ameliorates amyloid-β and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease. J Alzheimers Dis (2010) 1.00
Acetylcholinesterase and its inhibition in Alzheimer disease. Clin Neuropharmacol (2004) 1.00
N-terminal fragments of tau inhibit full-length tau polymerization in vitro. Biochemistry (2006) 0.99
Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease. Curr Alzheimer Res (2015) 0.98
Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity. J Med Chem (2003) 0.98
Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PLoS One (2012) 0.98
Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J Neurochem (2010) 0.97
Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid beta (A beta) peptide in the human neuroblastoma cells. Neurosci Lett (2009) 0.97
Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances? Alzheimers Dement (2012) 0.97
Pyridoxine-induced toxicity in rats: a stereological quantification of the sensory neuropathy. Exp Neurol (2004) 0.96
Alzheimer's disease drug development: old problems require new priorities. CNS Neurol Disord Drug Targets (2008) 0.96
Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides. J Pharmacol Exp Ther (2010) 0.96
Soluble neuroprotective antioxidant uric acid analogs ameliorate ischemic brain injury in mice. Neuromolecular Med (2007) 0.96
Resurrecting clinical pharmacology as a context for Alzheimer disease drug development. Curr Alzheimer Res (2009) 0.95
A new Alzheimer's disease interventive strategy: GLP-1. Curr Drug Targets (2004) 0.95
Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans. J Neurol Neurosurg Psychiatry (2012) 0.95
Neuropsychiatric clinical trials: should they accommodate real-world practices or set standards for clinical practices? J Clin Psychopharmacol (2009) 0.95
The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen. J Neural Transm (Vienna) (2011) 0.94
The anticholinesterase phenserine and its enantiomer posiphen as 5'untranslated-region-directed translation blockers of the Parkinson's alpha synuclein expression. Parkinsons Dis (2012) 0.94
A medical health report on individuals with silent butyrylcholinesterase in the Vysya community of India. Clin Chim Acta (2006) 0.94
A synopsis on the role of tyrosine hydroxylase in Parkinson's disease. CNS Neurol Disord Drug Targets (2012) 0.93
Novel p53 inactivators with neuroprotective action: syntheses and pharmacological evaluation of 2-imino-2,3,4,5,6,7-hexahydrobenzothiazole and 2-imino-2,3,4,5,6,7-hexahydrobenzoxazole derivatives. J Med Chem (2002) 0.93
Formation of phospho-SAPK/JNK granules in the hippocampus is an early event in Alzheimer disease. J Neuropathol Exp Neurol (2006) 0.93
Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. Age (Dordr) (2012) 0.93
N1phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: a comparison with donepezil and rivastigmine. Eur J Pharmacol (2007) 0.93
Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element. Int J Mol Sci (2009) 0.92
Phenserine efficacy in Alzheimer's disease. J Alzheimers Dis (2010) 0.92
Suppression of uracil-DNA glycosylase induces neuronal apoptosis. J Biol Chem (2004) 0.91
Brain pharmacokinetics of a nonpeptidic corticotropin-releasing factor receptor antagonist. Drug Metab Dispos (2002) 0.91
Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenet Genomics (2008) 0.91
Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine. J Med Chem (2005) 0.91
Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors. Eur J Med Chem (2011) 0.90
Intravenous butyrylcholinesterase administration and plasma and brain levels of cocaine and metabolites in rats. Eur J Pharmacol (2005) 0.90
Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice. Exp Neurol (2012) 0.90
Changes in mouse cognition and hippocampal gene expression observed in a mild physical- and blast-traumatic brain injury. Neurobiol Dis (2013) 0.90
Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine. Clin Neuropharmacol (2002) 0.89
Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice. Behav Brain Res (2011) 0.88
Early-life events may trigger biochemical pathways for Alzheimer's disease: the "LEARn" model. Biogerontology (2008) 0.88
Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J Med Chem (2006) 0.88
Differential accumulation of secreted AbetaPP metabolites in ocular fluids. J Alzheimers Dis (2010) 0.88
The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated region. Ann N Y Acad Sci (2004) 0.88
Decahydroisoquinoline derivatives as novel non-peptidic, potent and subtype-selective somatostatin sst(3) receptor antagonists. Bioorg Med Chem Lett (2010) 0.88
Lipid-lowering agents and the risk of cognitive impairment that does not meet criteria for dementia, in relation to apolipoprotein E status. Neuroepidemiology (2007) 0.87
Increasing the success rate for Alzheimer's disease drug discovery and development. Expert Opin Drug Discov (2012) 0.87
Cholesterol and Alzheimer's disease: clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors. Curr Drug Targets (2004) 0.87